An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood

被引:35
作者
Grebenchtchikov, N
Sweep, CGJ
Geurts-Moespot, A
Piffanelli, A
Foekens, JA
Benraad, TJ
机构
[1] Univ Nijmegen, Ctr Med, Dept Chem Endocrinol 530, Nijmegen, Netherlands
[2] Univ Ferrara, Dept Clin & Expt Med, Sect Nucl Med, Ferrara, Italy
[3] Rotterdam Canc Inst, Div Endocrine Oncol, Dept Med Oncol, Rotterdam, Netherlands
[4] Univ Rotterdam Hosp, Rotterdam, Netherlands
关键词
heterophilic antibodies; rheumatoid factor; ELISA; avian antibodies; serum; plasma;
D O I
10.1016/S0022-1759(02)00213-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Endogenous heterophilic antibodies in blood are known to interfere with two-site enzyme-linked immunosorbent assays (ELISAs) evoking false positive signals. In the present study, we describe an assay for the assessment of components of the plasminogen activation system (uPA, tPA and PAI-1, and their complexes) in blood which is not susceptible to interference by heterophilic antibodies. In the ELISA format, two avian (duck, chicken) antibodies are employed in the pre-analyte and two mammalian (rabbit, goat) antibodies in the post-analyte stage. The assay is compared to our earlier reported ELISA for measuring uPA, tPA and PAI-1 components in tumor tissue extracts. Applying the so-called "nonsense formats", designed against non-existent components, to the NIBSC reference preparation of rheumatoid factor (RF), no response was found with the new assay, whereas a clear RE dose-dependent interfering signal was observed with the original assay designed for tumor tissue extracts. Analysis of tumor-tissue based international reference preparations (RBG EORTC 10 1094 and 040297), human anti-mouse antibodies (HAMA) containing sera, and sera from patients with rheumatoid arthritis (RA), also displayed no false positive signals. In conclusion, we have developed an ELISA that permits the determination of blood levels of components in the urokinase system, free from disturbance by endogenous heterophilic antibodies. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:219 / 231
页数:13
相关论文
共 37 条
[1]   Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop [J].
Benraad, TJ ;
GeurtsMoespot, J ;
GrondahlHansen, J ;
Schmitt, M ;
Heuvel, JJTM ;
deWitte, JH ;
Foekens, JA ;
Leake, RE ;
Brunner, N ;
Sweep, CGJ .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (08) :1371-1381
[2]  
BOSCATO LM, 1986, CLIN CHEM, V32, P1491
[3]  
BOSCATO LM, 1988, CLIN CHEM, V34, P27
[4]  
CSAKO G, 1988, CLIN CHEM, V34, P1481
[5]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[6]   Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer [J].
de Witte, JH ;
Sweep, CGJ ;
Klijn, JGM ;
Grebenschikov, N ;
Peters, HA ;
Look, MP ;
van Tienoven, TH ;
Heuvel, JJTM ;
Vries, JBD ;
Benraad, TJ ;
Foekens, JA .
BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) :286-294
[7]   Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients [J].
de Witte, JH ;
Sweep, CGJ ;
Klijn, JGM ;
Grebenschikov, N ;
Peters, HA ;
Look, MP ;
van Tienoven, TH ;
Heuvel, JJTM ;
van Putten, WLJ ;
Benraad, TJ ;
Foekens, JA .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1190-1198
[8]  
DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO
[9]  
2-B
[10]  
Foekens JA, 2000, CANCER RES, V60, P636